Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lu-Dang-Shen oral liquid for digestive dysfunction in convalescent COVID-19 patients
ChiCTR2000032919Phase 4Recruiting
- Sponsor
- Wuhan Third Hospital
- Start
- May 2020
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Lu-Dang-Shen oral liquid in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Wuhan Third Hospital. Primary endpoint: Change in digestive dysfunction-related clinical symptom severity. Started May 2020; status: recruiting.
02
Drugs
Lu-Dang-Shen oral liquid
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2000032919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000032919.